Novo Nordisk’s patents on semaglutide, the active ingredient in Ozempic, are starting to expire. On today’s Big Take podcast, @davidgura talks to @naomikresge and @AmberTongPW about how the company is navigating a dire 2026 sales projection as generic versions are poised to upend.🎙️ Listen now: https://t.co/yT3DsoVeH6 ...

Novo Nordisk is predicting a 13% drop in sales in 2026. As the company’s patents on Ozempic expire, could cheaper, generic versions give the company a run for its money? Big Take host @davidgura talks to Bloomberg reporters @naomikresge and @AmberTongPW about what comes next https://t.co/HV0Hv3lWMT ...

Market Trends - The weight-loss drug market is expected to go truly global in 2026 due to the availability of cheap generic versions and new treatments in pill form [1]

Biocon plans to file for regulatory approvals of generic versions of Novo Nordisk A/S’s Ozempic and Wegovy in key markets https://t.co/4nfmYEbfo6 ...